Qin Ryan

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

Journal of Clinical Oncology · 2005 · First of 16 authors · 361 citations

Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies

Clinical Cancer Research · 2007 · 110 citations